全文获取类型
收费全文 | 6298篇 |
免费 | 401篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 179篇 |
妇产科学 | 79篇 |
基础医学 | 1038篇 |
口腔科学 | 149篇 |
临床医学 | 406篇 |
内科学 | 1485篇 |
皮肤病学 | 229篇 |
神经病学 | 552篇 |
特种医学 | 272篇 |
外国民族医学 | 1篇 |
外科学 | 696篇 |
综合类 | 17篇 |
预防医学 | 308篇 |
眼科学 | 220篇 |
药学 | 455篇 |
中国医学 | 20篇 |
肿瘤学 | 602篇 |
出版年
2023年 | 51篇 |
2022年 | 114篇 |
2021年 | 186篇 |
2020年 | 89篇 |
2019年 | 95篇 |
2018年 | 167篇 |
2017年 | 141篇 |
2016年 | 151篇 |
2015年 | 158篇 |
2014年 | 244篇 |
2013年 | 250篇 |
2012年 | 368篇 |
2011年 | 464篇 |
2010年 | 275篇 |
2009年 | 224篇 |
2008年 | 417篇 |
2007年 | 440篇 |
2006年 | 419篇 |
2005年 | 451篇 |
2004年 | 367篇 |
2003年 | 361篇 |
2002年 | 367篇 |
2001年 | 61篇 |
2000年 | 43篇 |
1999年 | 72篇 |
1998年 | 63篇 |
1997年 | 49篇 |
1996年 | 45篇 |
1995年 | 40篇 |
1994年 | 50篇 |
1993年 | 30篇 |
1992年 | 34篇 |
1991年 | 36篇 |
1990年 | 27篇 |
1989年 | 36篇 |
1988年 | 28篇 |
1987年 | 25篇 |
1986年 | 32篇 |
1985年 | 28篇 |
1984年 | 21篇 |
1983年 | 18篇 |
1982年 | 17篇 |
1981年 | 11篇 |
1979年 | 14篇 |
1978年 | 17篇 |
1976年 | 12篇 |
1974年 | 13篇 |
1971年 | 14篇 |
1969年 | 11篇 |
1965年 | 9篇 |
排序方式: 共有6742条查询结果,搜索用时 15 毫秒
1.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
2.
3.
Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk. 总被引:5,自引:0,他引:5
William D Leslie Colleen Metge Elizabeth A Salamon C Kin Yuen 《Journal of clinical densitometry》2002,5(2):117-130
The ease of measurement and the quantitative nature of bone mineral densitometry (BMD) is clinically appealing. Despite BMD's proven capability to stratify fracture risk, data indicate that clinical risk factors provide complementary information on fracture susceptibility that is independent of BMD. Methods to quantify fracture risk using both clinical and BMD variables would have great appeal for clinical decision-making. We describe a procedure for quantifying hip fracture risk (5-yr and remaining lifetime) based on (1) the individual's age alone (base model, assuming average clinical risk factors and bone density), (2) incorporation of multiple patient-specific clinical risk factor data in the base model, and (3) incorporation of both patient-specific clinical risk factor data and BMD results. 相似文献
4.
Nagai Masahiro Nishikawa Noriko Yabe Hayato Moritoyo Hiroyoko Moritoyo Takashi Shigematsu Yuji Nomoto Masahiro 《Journal of neurology》2007,254(4):IV54-IV57
Journal of Neurology - A high incidence of valvular heart disease in Parkinson's disease (PD) patients treated with ergot-derived dopamine agonists, such as cabergoline and pergolide, has been... 相似文献
5.
6.
Noriko Yoshimura Tomoko Takijiri Hirofumi Kinoshita Shigeto Danjoh Takahiro Kasamatsu Seiji Morioka Kiyomi Sakata Tsutomu Hashimoto Tatsuya Takeshita 《Osteoporosis international》2004,15(2):139-144
The aim of this study was to clarify and compare the temporal course of bone mineral density (BMD) between fast bone losers and normal residents in Miyama Village, a rural Japanese community. BMD was measured over a 10-year period in a cohort study in Miyama Village, Wakayama Prefecture, Japan, to provide information on rate of bone loss in the mature and elderly population. Subjects (n=400) were selected by sex and age stratum from the full list of residents born in 1910–1949, with 50 men and 50 women in each age decade. Baseline BMD of the lumbar spine and proximal femur was measured using dual energy X-ray absorptiometry in 1990, 1993, 1997 and 2000. In the cohort, 171 men and 189 women completed the follow-up survey performed in 1993. After calculating the rate of bone loss between 1990 and 1993, the greatest tertile from the distribution of bone loss was categorized as fast bone losers, with the remainder considered as normal subjects. Changes in BMD were compared between normal subjects and fast bone losers over the 10-year period. Mean rate of change for BMD at both lumbar spine and femoral neck in fast bone losers recovered to levels similar to those in normal subjects over 7 years of observation. By contrast, BMD at the lumbar spine and femoral neck decreased steeply over the 10-year period in both groups, and mean BMD for fast bone losers was significantly lower than that of normal subjects (P<0.05). These differences were apparent only at the lumbar spine in both men and women, even after adjusting for age. These results indicate that fast bone loss is a transient phenomenon rather than a fixed status, although individuals who have been categorized as fast bone losers at some stage continue to display low BMD in the lumbar spine. 相似文献
7.
Permanent prostate brachytherapy for Japanese men: Results from initial 100 patients with prostate cancer 总被引:1,自引:1,他引:0
Toshikazu Okaneya Shuji Nishizawa Tsuyoshi Nakayama Takayuki Kamigaito Iwao Hashida Noriko Hosaka 《International journal of urology》2007,14(7):602-606
OBJECTIVE: To evaluate the initial results of brachytherapy for prostate cancer with permanent iodine-125 implant in Japan. METHODS: The results obtained with brachytherapy in the initial 100 Japanese patients treated at Nagano Municipal Hospital were reviewed. Patients with a prostate-specific antigen (PSA) level of less than 10 ng/mL and a Gleason's scores of 5, 6, 3 + 4 were classified as having a low risk of recurrence. Patients with a PSA level of 10-20 ng/mL and/or a Gleason's score of 4 + 3 were classified as having an intermediate risk for recurrence. Seventy-eight of the low-risk patients and 19 of the intermediate-risk patients were treated by seed implants alone, or seed implants combined with preceding external radiation, respectively. A total of 53 patients received neoadjuvant hormone therapy. The efficacy and morbidity of brachytherapy were investigated using the serum PSA, International Prostate Symptom Score, quality of life score and uroflowmetry data. RESULTS: The average V100 and D90 obtained by post-implant dosimetry was 94.3 and 113.7%, respectively. Serum PSA decreased gradually after treatment, although it had still not reached a nadir after 1 year. There was little difference of the PSA level between the patients with and without neoadjuvant hormone therapy even at 1 year after seed implantation. There were no PSA biochemical failure or clinical recurrence during the follow-up period. Voiding symptoms worsened until 3 months after treatment, and then gradually improved. Acute urinary retention occurred transiently in one patient (1%). Rectal bleeding and severe diarrhea did not occur. CONCLUSION: Brachytherapy is a feasible and effective option for the treatment of prostate cancer in Japanese men. Brachytherapy may have a different effect in Japanese patients with respect to voiding symptoms. Urinary retention was rare, but voiding symptoms were persistent in Japanese patients. Neoadjuvant hormone therapy deserves investigation to determine whether it can achieve better results, especially in patients with an intermediate risk. 相似文献
8.
9.
10.
Patients with non-insulin-dependent diabetes mellitus (NIDDM) who have chronic hyperglycemia lose acute incremental insulin responses to glucose but are able to briskly respond to other beta-cell secretagogues. To investigate whether this is a defect specific for glucose or represents a more general phenomenon, we measured the insulin responses to acute intravenous tolbutamide in 10 obese patients with NIDDM both before and during sulfonylurea therapy with tolazamide. Comparable glycemia was achieved with oral dextrose 2 h before intravenous testing. To assess beta-cell responsiveness to a nonsulfonylurea secretagogue, 1 mg glucagon was administered intravenously during tolazamide therapy. In seven patients, the mean peak insulin increment 5 or 10 min after intravenous tolbutamide was 54 +/- 11 microU/ml when not receiving tolazamide (0.14 +/- 1.3 microU/ml) with tolazamide (P less than .001), even though serum insulin responded rapidly to intravenous glucagon. In four patients tested for reversibility of their refractoriness to intravenous tolbutamide during chronic tolazamide therapy, the mean peak insulin increment 1 wk after discontinuing tolazamide was 79 +/- 22 microU/ml. A relatively rapid development of refractoriness was documented in four patients who were tested only 12 h after beginning tolazamide therapy; the mean peak insulin increments 5-10 min after intravenous tolbutamide were undetectable (-0.5 microU/ml), yet responses to intravenous glucagon were evident. In these NIDDM patients, exposure of pancreatic beta-cells to sustained levels of sulfonylureas induces a reversible state of refractoriness to acute stimulation with sufonylureas but not to another secretagogue.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献